In patients with progressive MS, improved symptoms correlated with higher serum levels of IFNγ [24] and intraventricular administration of IFNγ during chronic stages of EAE resulted in reduced disease severity and mortality in marmosets and rats [25, 26]. Here, IFNG is linked to myeloid sarcoma.